苯磺酰胺装饰的二氢嘧啶(硫):碳酸酐酶分析和抗增殖活性

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-03-26 DOI:10.1039/D4MD00101J
Hakan Aslan, Gioele Renzi, Andrea Angeli, Ilaria D'Agostino, Roberto Ronca, Maria Luisa Massardi, Camilla Tavani, Simone Carradori, Marta Ferraroni, Paolo Governa, Fabrizio Manetti, Fabrizio Carta and Claudiu T. Supuran
{"title":"苯磺酰胺装饰的二氢嘧啶(硫):碳酸酐酶分析和抗增殖活性","authors":"Hakan Aslan, Gioele Renzi, Andrea Angeli, Ilaria D'Agostino, Roberto Ronca, Maria Luisa Massardi, Camilla Tavani, Simone Carradori, Marta Ferraroni, Paolo Governa, Fabrizio Manetti, Fabrizio Carta and Claudiu T. Supuran","doi":"10.1039/D4MD00101J","DOIUrl":null,"url":null,"abstract":"<p >In the last decades, carbonic anhydrases (CAs) have become the top investigated innovative pharmacological targets and, in particular, isoforms IX and XII have been widely studied due to the evidence of their overexpression in hypoxic tumors. The frantic race to find new anticancer agents places the quick preparation of large libraries of putative bioactive compounds as the basis of a successful drug discovery and development programme. In this context, multi-component and, in general, one-step reactions are becoming very popular and, among them, Biginelli's reaction gave clean and easy-to-isolate products. Thus, we synthesized a series of Biginelli's products (<strong>10–17a–b</strong>) and similar derivatives (<strong>20–21</strong>) bearing the benzenesulfonamide moiety, which is known to inhibit CA enzymes. Through the stopped-flow technique, we were able to assess their ability to inhibit the targeted CAs IX and XII in the nanomolar range with promising selectivity over the physiologically relevant isoforms I and II. Crystallography studies and docking simulations helped us to gain insight into the interaction patterns established in the enzyme–inhibitor complex. From a chemical similarity-based screening of in-house libraries of compounds, a diphenylpyrimidine (<strong>23</strong>) emerged. The surprisingly potent inhibitory activity of <strong>23</strong> for CAs IX and XII along with its strong antiproliferative effect on two (triple-negative breast cancer MDA-MB-231 and glioblastoma U87MG) cell lines laid the foundation for further investigation, again confirming the key role of CAs in cancer.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 6","pages":" 1929-1941"},"PeriodicalIF":3.5970,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00101j?page=search","citationCount":"0","resultStr":"{\"title\":\"Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity†\",\"authors\":\"Hakan Aslan, Gioele Renzi, Andrea Angeli, Ilaria D'Agostino, Roberto Ronca, Maria Luisa Massardi, Camilla Tavani, Simone Carradori, Marta Ferraroni, Paolo Governa, Fabrizio Manetti, Fabrizio Carta and Claudiu T. Supuran\",\"doi\":\"10.1039/D4MD00101J\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >In the last decades, carbonic anhydrases (CAs) have become the top investigated innovative pharmacological targets and, in particular, isoforms IX and XII have been widely studied due to the evidence of their overexpression in hypoxic tumors. The frantic race to find new anticancer agents places the quick preparation of large libraries of putative bioactive compounds as the basis of a successful drug discovery and development programme. In this context, multi-component and, in general, one-step reactions are becoming very popular and, among them, Biginelli's reaction gave clean and easy-to-isolate products. Thus, we synthesized a series of Biginelli's products (<strong>10–17a–b</strong>) and similar derivatives (<strong>20–21</strong>) bearing the benzenesulfonamide moiety, which is known to inhibit CA enzymes. Through the stopped-flow technique, we were able to assess their ability to inhibit the targeted CAs IX and XII in the nanomolar range with promising selectivity over the physiologically relevant isoforms I and II. Crystallography studies and docking simulations helped us to gain insight into the interaction patterns established in the enzyme–inhibitor complex. From a chemical similarity-based screening of in-house libraries of compounds, a diphenylpyrimidine (<strong>23</strong>) emerged. The surprisingly potent inhibitory activity of <strong>23</strong> for CAs IX and XII along with its strong antiproliferative effect on two (triple-negative breast cancer MDA-MB-231 and glioblastoma U87MG) cell lines laid the foundation for further investigation, again confirming the key role of CAs in cancer.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 6\",\"pages\":\" 1929-1941\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2024-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00101j?page=search\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00101j\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00101j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

在过去几十年中,碳酸酐酶(CAs)已成为研究的首要创新药理靶点,尤其是同工酶 IX 和 XII,由于它们在缺氧肿瘤中过度表达的证据而被广泛研究。为寻找新的抗癌药物而展开的疯狂竞赛,使快速制备大型假定生物活性化合物库成为药物发现和开发计划取得成功的基础。在这种情况下,多组分反应和一般的一步反应正变得非常流行,其中,Biginelli 反应可以得到干净且易于分离的产物。因此,我们合成了一系列 Biginelli 产物(10-17a-b)和带有苯磺酰胺分子的类似衍生物(20-21)。通过停流技术,我们能够评估它们在纳摩尔范围内抑制目标 CA IX 和 XII 的能力,并对生理相关的同工酶 I 和 II 具有良好的选择性。晶体学研究和对接模拟帮助我们深入了解了酶抑制剂复合物中的相互作用模式。通过对内部化合物库进行基于化学相似性的筛选,我们发现了一种二苯基嘧啶(23)。23 对 CAs IX 和 XII 具有令人惊讶的强效抑制活性,同时对两种细胞系(三阴性乳腺癌 MDA-MB-231 和胶质母细胞瘤 U87MG)具有很强的抗增殖作用,这为进一步研究奠定了基础,再次证实了 CAs 在癌症中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity†

In the last decades, carbonic anhydrases (CAs) have become the top investigated innovative pharmacological targets and, in particular, isoforms IX and XII have been widely studied due to the evidence of their overexpression in hypoxic tumors. The frantic race to find new anticancer agents places the quick preparation of large libraries of putative bioactive compounds as the basis of a successful drug discovery and development programme. In this context, multi-component and, in general, one-step reactions are becoming very popular and, among them, Biginelli's reaction gave clean and easy-to-isolate products. Thus, we synthesized a series of Biginelli's products (10–17a–b) and similar derivatives (20–21) bearing the benzenesulfonamide moiety, which is known to inhibit CA enzymes. Through the stopped-flow technique, we were able to assess their ability to inhibit the targeted CAs IX and XII in the nanomolar range with promising selectivity over the physiologically relevant isoforms I and II. Crystallography studies and docking simulations helped us to gain insight into the interaction patterns established in the enzyme–inhibitor complex. From a chemical similarity-based screening of in-house libraries of compounds, a diphenylpyrimidine (23) emerged. The surprisingly potent inhibitory activity of 23 for CAs IX and XII along with its strong antiproliferative effect on two (triple-negative breast cancer MDA-MB-231 and glioblastoma U87MG) cell lines laid the foundation for further investigation, again confirming the key role of CAs in cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Introduction to the themed collection in honour of Professor Christian Leumann Back cover Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy Introduction to the themed collection on ‘AI in Medicinal Chemistry’
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1